Patents by Inventor Shawn Branum

Shawn Branum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRF RECEPTOR ANTAGONISTS AND METHODS OF USE
    Publication number: 20230065034
    Abstract: Compounds are provided herein that antagonize corticotropin-releasing factor (CRF) receptors, in particular CRF receptor 1 (CRF1), as well as related preparations, compositions and methods for treating diseases and/or disorders that would benefit from the same such as congenital adrenal hyperplasia (CAH).
    Type: Application
    Filed: December 1, 2020
    Publication date: March 2, 2023
    Inventors: Neil J. ASHWEEK, John P. WILLIAMS, Lev Alexander ZEGELMAN, Christina Marie COSTA, Scott STIRN, Shawn BRANUM, Jackie LE, John Lloyd TUCKER, Brian M. COCHRAN, David KUCERA, Donald HETTINGER, Max A. MELLMER
  • PROCESSES FOR THE SYNTHESIS OF VALBENAZINE
    Publication number: 20220363680
    Abstract: The present application relates to processes for making (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b -hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl (S)-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), which is an inhibitor of vesicular monoamine transporter 2 (VMAT2) useful in the treatment of hyperkinetic movement disorders such as tardive dyskinesia (TD).
    Type: Application
    Filed: September 11, 2020
    Publication date: November 17, 2022
    Inventors: John TUCKER, David KUCERA, Donald HETTINGER, Brian M. COCHRAN, Shawn BRANUM, Jackie LE, Kevin MCGEE
  • VMAT2 inhibitor compounds and compositions thereof
    Patent number: 11040970
    Abstract: Provided is a compound selected from compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof: (I) wherein R1, R2, R3 and R4 are as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, neurological and psychiatric diseases and disorders. Also disclosed are compositions containing such compounds in combination with a pharmaceutically acceptable carrier, as well as methods relating to their use in subjects in need thereof.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: June 22, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Nicole Harriott, Donald Hettinger, Shawn Branum, Jeffrey C. Culhane
  • Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
    Patent number: 10919892
    Abstract: Provided herein are processes for the preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: February 16, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Kevin McGee, Bin-Feng Li, Shawn Branum
  • Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
    Patent number: 10906903
    Abstract: Provided herein are processes for the preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: February 2, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Kevin McGee, Bin-Feng Li, Shawn Branum
  • Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
    Patent number: 10906902
    Abstract: Provided herein are processes for the preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: February 2, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Kevin McGee, Bin-Feng Li, Shawn Branum
  • VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF
    Publication number: 20200131173
    Abstract: Provided is a compound selected from compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof: (I) wherein R1, R2, R3 and R4 are as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, neurological and psychiatric diseases and disorders. Also disclosed are compositions containing such compounds in combination with a pharmaceutically acceptable carrier, as well as methods relating to their use in subjects in need thereof.
    Type: Application
    Filed: April 17, 2018
    Publication date: April 30, 2020
    Inventors: Nicole Harriott, Donald Hettinger, Shawn Branum, Jeffrey C. Culhane
  • Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators
    Patent number: 9718820
    Abstract: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 1, 2017
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Mark R. Player, Raul Calvo, Jinsheng Chen, Sanath Meegalla, Daniel J. Parks, William J. Parsons, Scott Ballentine, Shawn Branum
  • Process for the preparation of compounds useful as inhibitors of SGLT-2
    Patent number: 9522931
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: December 20, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kenneth M. Wells, Ronald K. Russell, Xun Li, Shawn Branum, Derek A. Beauchamp, Sumihiro Nomura, Yosuke Matsumura
  • SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS
    Publication number: 20160304518
    Abstract: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    Type: Application
    Filed: June 29, 2016
    Publication date: October 20, 2016
    Inventors: Mark R. Player, Raul Calvo, Jinsheng Chen, Sanath Meegalla, Daniel J. Parks, William J. Parsons, Scott Ballentine, Shawn Branum
  • Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
    Patent number: 9409915
    Abstract: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: August 9, 2016
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark R. Player, Raul Calvo, Jinsheng Chen, Sanath Meegalla, Daniel J. Parks, William J. Parsons, Scott Ballentine, Shawn Branum
  • Fused cyclopentyl antagonists of CCR2
    Patent number: 9150532
    Abstract: The present invention comprises processes for preparing compounds of Formula (I). wherein: R0, R1, R2, R3, R4, R5, and A are as defined in the specification.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: October 6, 2015
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Shawn Branum, Michael Reuman, Ronald K Russell, Christopher A. Teleha
  • SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS
    Publication number: 20150158875
    Abstract: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    Type: Application
    Filed: February 17, 2015
    Publication date: June 11, 2015
    Inventors: Mark R. Player, Raul Calvo, Jinsheng Chen, Sanath Meegalla, Daniel J. Parks, William J. Parsons, Scott Ballentine, Shawn Branum
  • Substituted AZA-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
    Patent number: 9023846
    Abstract: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: May 5, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark R Player, Raul Calvo, Jinsheng Chen, Sanath Meegalla, Daniel J. Parks, William J Parsons, Scott Ballentine, Shawn Branum
  • FUSED CYCLOPENTYL ANTAGONISTS OF CCR2
    Publication number: 20150080588
    Abstract: The present invention comprises processes for preparing compounds of Formula (I). wherein: R0, R1, R2, R3, R4, R5, and A are as defined in the specification.
    Type: Application
    Filed: July 24, 2014
    Publication date: March 19, 2015
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Shawn Branum, Michael Reuman, Ronald K. Russell, Christopher A. Teleha
  • PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT-2
    Publication number: 20140206858
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Application
    Filed: May 18, 2012
    Publication date: July 24, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Kenneth M. Wells, Ronald K. Russell, Xun Li, Shawn Branum, Derek A. Beauchamp, Sumihiro Nomura, Yosuke Matsumura
  • PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT-2
    Publication number: 20140206859
    Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.
    Type: Application
    Filed: May 18, 2012
    Publication date: July 24, 2014
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Kenneth M. Wells, Xun Li, Shawn Branum, Sumihiro Nomura, Yosuke Matsumura
  • SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS
    Publication number: 20140155395
    Abstract: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    Type: Application
    Filed: February 4, 2014
    Publication date: June 5, 2014
    Applicant: Janssen Pharmaceutica, NV
    Inventors: Mark R. Player, Raul Calvo, Jinsheng Chen, Sanath Meegalla, Daniel Parks, William Parsons, Scott Ballentine, Shawn Branum
  • Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
    Patent number: 8680098
    Abstract: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: March 25, 2014
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Mark R. Player, Raul Calvo, Jinsheng Chen, Sanath Meegalla, Daniel Parks, William Parsons, Scott Ballentine, Shawn Branum
  • SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS
    Publication number: 20110218197
    Abstract: The present invention is directed to substituted aza-bicyclic imidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8, including for example, inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold and pulmonary disease aggravated by cold.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 8, 2011
    Inventors: Mark R. PLAYER, Raul Calvo, Jinsheng Chen, Sanath Meegalla, Daniel Parks, William Parsons, Scott Ballentine, Shawn Branum